Stock AnalizCytokinetics Inc. CYTK
Biotechnology: Pharmaceutical Preparations · IPO 2004 · data as of November 13, 2026
Cytokinetics Inc. (CYTK) is a healthcare company listed in the US with a market value of about $7.8B. In the twelve months to September 30, 2026 it had revenue of $113M and net income of -$778M, a net margin of -686.6%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 10% a year, a 5-year average ROIC of -69%.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $113M | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M |
| Net income | -$778M | -$785M | -$590M | -$526M | -$389M | -$215M | -$127M | -$122M | -$106M | -$128M | $16M |
| Free cash flow | -$589M | -$535M | -$400M | -$416M | -$311M | -$191M | -$2M | -$94M | -$102M | -$105M | $35M |
| EPS (diluted) | $-6.04 | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | $-2.11 | $-1.95 | $-2590.00 | $390.00 |
| Net margin | -686.6% | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% |
| ROIC | — | -103.7% | -68.8% | -100.2% | -37.6% | -35.2% | -45.6% | -190.8% | -112.5% | -80.1% | 15.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 19 analysts is $109.42, 95% above the current price; targets range from $78.00 to $146.00; the consensus rating is “Strong buy”; expected EPS is $-5.76 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Cytokinetics pay a dividend?
Not currently.
Is Cytokinetics a good stock to buy?
We do not give buy or sell advice. Cytokinetics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.